Abstract: SA-PO304
Diagnostic Accuracy of MicroRNAs in Diabetic Nephropathy: A Meta-Analysis
Session Information
- Diabetic Kidney Disease: Clinical Pathology, Diagnostic and Treatment Advances
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Garmaa, Gantsetseg, Semmelweis Egyetem, Budapest, Budapest, Hungary
- Kói, Tamás, Budapesti Muszaki es Gazdasagtudomanyi Egyetem, Budapest, Budapest, Hungary
Background
MiRNAs play a significant role in the pathophysiology of diabetic nephropathy (DN), as demonstrated by numerous preclinical and cohort studies. They are potential diagnostic biomarkers but also promising therapeutic agents. However, to accelerate their clinical application, it is crucial to systematically review and summarize their diagnostic performance in various biological samples during DN.
Methods
The systematic search involves five databases following the PROSPERO CRD42021282785 protocol. The study includes individuals with DN and those without (healthy or with diabetes mellitus (DM)). MiRNA detection using qRT-PCR is the index test, while clinical diagnoses confirmed by biopsy or laboratory results serve as reference tests. For meta-analyses, the area under the curve (AUC) sensitivity (SEN), and specificity (SPE) of single or panel miRNAs from each study were extracted and analyzed using R software.
Results
Eighty-seven studies met the eligibility criteria, all included in the meta-analysis. The pooled SEN and SPE results in DN compared to healthy controls for single miRNAs were 0.91 (95% CI: 0.86–0.95) and 0.89 (95% CI: 0.77–0.95), respectively. When DN was compared to DM patients, the pooled SEN and SPE were 0.82 (95% CI; 0.76-0.87) and 0.81 (95% CI; 0.74-0.86) for single miRNAs.
In the DN with healthy control, only AUC values for a panel of miR-15b, miR-34a, and miR-636 were reported (0.91, 95% CI; 0.86-0.96), and pooled AUC (pAUC) for single miRNAs was 0.85 (95% CI; 0.81-0.89). The pAUC of DN vs. DM was 0.86 (95% CI; 0.82-0.91) for panel miRNAs and 0.79 (95% CI; 0.75-0.82) for single miRNAs.
Among the individual studies, a panel of miR-21 and miR-30-b-5p showed a higher AUC in DN patients than in DM patients, 0.93 (95% CI; 0.86–1.0). For DN, blood samples outperformed urine, with a pAUC of 0.87 compared to 0.84.
Conclusion
MiRNAs can differentiate between DN patients, healthy individuals, and patients with DM. Using miRNA panels for diagnosis is more effective than relying on a single miRNA. Additional large cohorts should investigate the diagnostic performance of miRNAs in different stages of DN and biological sample types.
Funding
- Government Support – Non-U.S.